Patent office upholds key patent for Gilead's HIV drug

05/21/2008 | Boston Globe (tiered subscription model), The

Gilead Sciences announced that the U.S. Patent and Trademark Office has reaffirmed one of four key patents for its HIV drug Viread. The patents are being reassessed after being challenged by the Public Patent Foundation, which has claimed prior art. The patent office will likely uphold the other three patents, an analyst said.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ